Health · September 12, 2026 · 11 min read

The Menopause Study Every Woman—and Every Doctor—Should Be Talking About

A fascinating 2026 study found modern menopausal hormone therapy could improve quality-adjusted life expectancy while reducing projected healthcare costs. Here's what women should know about estrogen, progesterone and HRT.

For more than two decades, women have been told to be afraid of hormone replacement therapy.

Now a fascinating new study is asking us to look at the conversation very differently.

And after reading it, I keep coming back to one thought: why isn't every doctor discussing this information with their female patients approaching menopause?

A new study published in Obstetrics & Gynecology examined the potential long-term health and economic effects of modern menopausal hormone therapy (MHT). The results were remarkable.

The researchers' model found that, for typical 50-year-old women experiencing menopausal symptoms, modern hormone therapy wasn't merely cost-effective. It produced better projected health outcomes while costing the healthcare system less.

That's a conversation I believe women deserve to have.

How did we become so afraid of hormones?

To understand why this study matters, we need to go back to 2002.

The Women's Health Initiative dramatically changed how America viewed hormone therapy after the estrogen-plus-progestin portion of the trial was stopped early amid concerns involving breast cancer and cardiovascular risks.

The headlines were enormous. The nuance wasn't.

An entire generation of women came away from that period with a remarkably simple message—"hormones cause cancer."

Twenty-four years later, our understanding of menopausal hormone therapy is considerably more nuanced, including differences involving the patient's age, timing of treatment, route of estrogen administration and type of progestogen.

And this new research evaluated therapies that more closely resemble modern treatment.

The new study

Researchers from Walter Reed National Military Medical Center and Uniformed Services University created a Markov model following hypothetical 50-year-old women with menopausal vasomotor symptoms over their lifetimes.

They compared no hormone therapy with five years of transdermal estradiol for women without a uterus, or transdermal estradiol plus micronized progesterone for women with a uterus.

The model incorporated published evidence involving cardiovascular disease, cancer, hip fractures, mortality, healthcare costs and quality of life.

That distinction matters. This wasn't simply a model of "HRT" as one giant category. It specifically examined transdermal estradiol and micronized progesterone, rather than assuming every hormone, dose and delivery method has the same risk-benefit profile.

The results are fascinating

Here's where I think every woman—and every physician caring for women around menopause—should pay attention.

For every 10,000 women modeled over their lifetimes, transdermal estradiol compared with no MHT was associated with:

$135.4 million lower healthcare costs
647 fewer deaths
259 fewer cases of atherosclerotic cardiovascular disease
181 fewer hip fractures
105 fewer colon cancers
33,196 additional quality-adjusted life years

For women receiving estradiol plus micronized progesterone, the model projected:

$127.7 million lower healthcare costs
615 fewer deaths
285 fewer cases of atherosclerotic cardiovascular disease
183 fewer hip fractures
33,083 additional quality-adjusted life years

Those are extraordinary projections.

Summarized per person, that's roughly $13,000 in lifetime healthcare savings per woman and about 3.3 additional quality-adjusted life years.

And in the study's probabilistic sensitivity analysis, both hormone-therapy strategies remained dominant—producing better modeled outcomes at lower cost—across the willingness-to-pay thresholds tested.

But there's an important detail we shouldn't leave out

If we're going to talk about women's hormones honestly, we should talk about the entire result—not cherry-pick the exciting parts.

The model also projected 87 additional breast cancer cases per 10,000 women receiving estradiol alone and 46 additional breast cancer cases in the estradiol-plus-micronized-progesterone strategy versus no MHT.

Interestingly, despite those projected increases, the overall model still favored hormone therapy because of its combined effects on mortality, cardiovascular disease, fractures, quality of life and healthcare costs.

That doesn't mean hormone therapy is right for every woman.

It means the discussion is much more sophisticated than "hormones are good" or "hormones are dangerous."

And that's exactly why women need individualized conversations with knowledgeable clinicians.

Heart health appears to be a huge part of the equation

One of the most interesting findings was why hormone therapy performed so well economically.

According to the researchers, changes in atherosclerotic cardiovascular disease risk were the largest driver of cost-effectiveness in their model.

Think about that.

For years, many women have primarily thought about hormone therapy as something you consider when hot flashes become unbearable. This research asks us to think much bigger.

Menopause isn't merely about hot flashes.

It's a major biological transition occurring during decades of a woman's life when cardiovascular health, bone health, metabolic health and quality of life increasingly matter.

That's why I find this research so fascinating.

There's something else the study didn't measure

The model evaluated several major clinical outcomes, but it wasn't designed to capture every symptom or quality-of-life issue women associate with menopause—areas such as sleep, mood, cognition, muscle mass and sexual function weren't individually modeled as outcomes in this analysis.

Those aren't trivial concerns.

Ask a woman struggling through menopause whether sleep, mood, mental sharpness, strength or sexual health affects her quality of life. Of course it does.

But we should be careful about concluding that adding those outcomes would necessarily have made the numerical results even better. That's an interesting possibility, not something this study demonstrated.

And what about testosterone?

This study evaluated menopausal hormone therapy using estradiol with or without micronized progesterone. It did not evaluate testosterone therapy.

That's a separate conversation.

Testosterone can have an evidence-based role for selected postmenopausal women—particularly in the treatment of hypoactive sexual desire disorder—but this study cannot tell us whether adding testosterone would increase longevity or healthcare savings. It's an interesting area for future research.

Here's the part I want women to take away from this

I'm not suggesting that every woman should walk into her doctor's office tomorrow and demand hormones.

I'm saying every woman deserves the conversation. There is an enormous difference.

Menopausal hormone therapy has contraindications and risks. Your age, symptoms, personal and family medical history, uterus status, cardiovascular risk, breast cancer risk and other factors matter.

But women shouldn't spend years suffering—or automatically dismiss hormone therapy—because of a frightening headline they remember from 2002.

The science has continued evolving. Our conversations should evolve with it.

Every doctor caring for women should be discussing this

This is the part I feel strongly about.

This is fascinating information that I believe every doctor caring for women approaching or experiencing menopause should know about and be prepared to discuss with their patients.

Not because this single study proves that hormone therapy will make every woman live longer. It doesn't.

This was a modeling analysis based on existing evidence, and models depend on their underlying assumptions. Previous reviews of hormone-therapy cost-effectiveness research have specifically cautioned that these analyses can be sensitive to assumptions about quality of life and long-term disease risks.

But the findings are simply too interesting to ignore.

A contemporary model using transdermal estradiol and micronized progesterone projected lower healthcare costs, fewer cardiovascular events and hip fractures, fewer deaths and substantially more quality-adjusted life years compared with no hormone therapy in symptomatic women beginning treatment at age 50.

That deserves a conversation.

Especially when so many women still enter perimenopause and menopause with very little understanding of what's happening to their bodies or what treatment options are available.

At Rise, we want women asking better questions

At Rise Wellness & Longevity, one of our biggest goals is education.

We want women to understand their bodies well enough to walk into a healthcare appointment and ask:

Could my symptoms be related to changing hormones?
Am I an appropriate candidate for menopausal hormone therapy?
What are my individual risks and potential benefits?
Does the type of estrogen, route of administration or progesterone used matter for me?

Those are much better questions than simply assuming menopause is something you're supposed to suffer through.

Medicine should never be about blindly putting everyone on hormones. But it shouldn't be about blindly keeping everyone off them either.

Women deserve the information. Women deserve an individualized risk-benefit discussion. And women deserve clinicians willing to have it.

That's why I think this new study is so important. The conversation around menopause is changing—and it's long overdue.

Read the study on PubMed

This article is for educational purposes and is not medical advice. Menopausal hormone therapy has potential benefits, risks and contraindications and should be individualized by a qualified healthcare professional. The 2026 study discussed above is a cost-effectiveness modeling analysis; its projected outcomes should not be interpreted as proof that MHT prevents disease or extends life for an individual patient.

Sources

Find your protocol All articles